Back to Peptides

AOD-9604

Well Studied

Modified hGH Fragment | Fat Loss Peptide

Dose 250-500mcg
Frequency Once daily
Cycle 8-12 weeks
Storage Lyophilized: room temp or freezer long-term. Reconstituted: 2-8°C for 28 days
Accumulation Plotter

AOD-9604 is a modified fragment of human growth hormone (amino acids 176-191) that stimulates lipolysis and inhibits lipogenesis without the side effects of full growth hormone. Unlike full GH, it does not increase IGF-1, affect glucose metabolism, or cause insulin resistance.

Mechanism of Action

Stimulates lipolysis and inhibits lipogenesis through beta-3 adrenergic receptor upregulation, without binding to the GH receptor. Does not affect glucose metabolism or increase IGF-1 levels.

Key Benefits

  • Targets fat loss through selective lipolysis
  • Avoids growth hormone side effects
  • No effect on blood glucose or insulin
  • Does not increase IGF-1 levels
  • Metabolically safer than full hGH
  • Emerging cartilage repair potential
Molecular Weight
1,815.1 Da
Chain Length
17 amino acids
Type
Modified hGH C-terminal fragment
Amino Acid Sequence
One-letter: YLRIVQCRSVEGSCGF
H₂N
Y 1
O ‖ C
N
L 2
O ‖ C
N
R 3
O ‖ C
N
I 4
O ‖ C
N
V 5
O ‖ C
N
Q 6
O ‖ C
N
C 7
O ‖ C
N
R 8
O ‖ C
N
S 9
O ‖ C
N
V 10
O ‖ C
N
E 11
O ‖ C
N
H
G 12
O ‖ C
N
S 13
O ‖ C
N
C 14
O ‖ C
N
H
G 15
O ‖ C
N
F 16
COOH
Tyr
1

Tyrosine

Position 1

Leu
2

Leucine

Position 2

Arg
3

Arginine

Position 3

Ile
4

Isoleucine

Position 4

Val
5

Valine

Position 5

Gln
6

Glutamine

Position 6

Cys
7

Cysteine

Position 7

Arg
8

Arginine

Position 8

Ser
9

Serine

Position 9

Val
10

Valine

Position 10

Glu
11

Glutamic Acid

Position 11

Gly
12

Glycine

Position 12

Ser
13

Serine

Position 13

Cys
14

Cysteine

Position 14

Gly
15

Glycine

Position 15

Phe
16

Phenylalanine

Position 16

N-terminus C-terminus
Hydrophobic
Polar
Positive (+)
Negative (-)
Modified

Fat Loss

  • Lipolysis Enhancement

    Increases fat oxidation, plasma glycerol levels, and reduces body weight in obese models without affecting glucose metabolism.

  • Lipogenesis Inhibition

    Reduces fat synthesis and storage in adipose tissue.

  • Metabolic Safety

    Does not cause hyperglycemia, reduce insulin secretion, or increase insulin resistance.

Joint Health

  • Cartilage Repair

    Enhanced cartilage regeneration when combined with hyaluronic acid in osteoarthritis models.

  • Osteoarthritis Support

    Synergistic effects with hyaluronic acid for joint health.

Subcutaneous injection is the standard route. Administer in the morning on an empty stomach, wait 30 minutes before eating for optimal results.

GoalDoseFrequencyRoute
Fat loss - Standard250-300mcgOnce daily (morning, fasted)SubQ
Enhanced fat loss400-500mcgOnce daily (morning, fasted)SubQ
Joint support250mcgOnce dailySubQ
Conservative start200mcgOnce dailySubQ

Reconstitution Instructions

Materials Needed:
  • Lyophilized AOD-9604 vial
  • Bacteriostatic water (BAC water)
  • Insulin syringes (0.5-1mL)
  • Alcohol swabs
  • Sterile work surface
  1. 1 Allow vial to reach room temperature (15-20 minutes)
  2. 2 Calculate required bacteriostatic water volume
  3. 3 Clean vial stopper with alcohol swab
  4. 4 Draw BAC water into syringe
  5. 5 Inject slowly down vial side (not directly onto powder)
  6. 6 Gently swirl until dissolved (never shake vigorously)
  7. 7 Store reconstituted solution at 2-8°C
  8. 8 Use within 28 days
Hyaluronic Acid

Enhanced cartilage repair when combined for joint health.

synergistic
BPC-157

Different mechanisms; sometimes combined for comprehensive healing.

compatible
CJC-1295

AOD-9604 doesn't affect GH axis; can be used together.

compatible
Ipamorelin

Different mechanisms; no known interactions.

compatible
Semaglutide

Complementary weight loss mechanisms through different pathways.

compatible
Insulin

AOD-9604 doesn't affect glucose metabolism unlike full hGH.

compatible
Week 1-2

Minimal noticeable effects; compound accumulating

Week 3-4

Subtle body composition changes may begin

Week 5-8

More noticeable fat loss, especially with diet and exercise

Week 8-12

Continued fat reduction and improved body composition

Common Side Effects

  • Generally well-tolerated in clinical trials
  • Mild injection site reactions possible
  • No reported effects on blood glucose or insulin

Stop Signs - Discontinue if:

  • Severe injection site reactions or infection signs
  • Unusual swelling or persistent redness
  • Allergic reactions (rare)
  • Any concerning or unexpected symptoms

Contraindications

  • Pregnancy or breastfeeding
  • WADA prohibited - athletes subject to testing must avoid

Good Signs

  • White lyophilized powder with uniform appearance
  • Crystal clear solution without particles after reconstitution
  • Certificate of Analysis showing >98% purity by HPLC
  • Proper cold-chain shipping

Warning Signs

  • Not FDA approved as a therapeutic drug - research chemical only
  • WADA prohibited substance

Bad Signs

  • Discolored or clumped powder (yellow indicates degradation)
  • Cloudy solution after reconstitution
  • Collapsed or moisture-damaged appearance
  • Fat Oxidation and Weight Loss in Obese Mice - Heffernan et al.
    International Journal of Obesity (2001)

    AOD-9604 reduced body weight without hyperglycemia through enhanced fat oxidation.

  • Beta-3 Adrenergic Receptor Mechanism - Heffernan et al.
    Endocrinology (2001)

    Increased beta-3 adrenergic receptor expression comparable to lean mice.

  • Oral Lipid Metabolism Effects - Heffernan et al.
    American Journal of Physiology (2000)

    Significantly reduced lipogenic activity and increased lipolytic activity.

  • Cartilage Regeneration with Hyaluronic Acid - Kwon & Park
    Annals of Clinical and Laboratory Science (2015)

    Combination accelerated cartilage regeneration in osteoarthritis models.

Disclaimer

This information is for educational and research purposes only. Consult a healthcare professional before use.